By Dean SealShares of INmune Bio fell after the company said the study for its Alzheimer's disease treatment would remain on full clinical hold. Shares had gained 82% year-to-date when the market closed Monday. The Boca Raton, Fla.-based immunology company said after the bell Monday that the U.S. Food and Drug Administration had requested additional information on the long-term potency of the treatment. INmune Bio said it would provide clarification to the FDA in response before the end of the year, which it believes will resolve remaining questions. The FDA is the only regulatory agency to put the trial on hold, and patient recruitment projections don't rely on any sites in the U.S., the company said.

Source: Wall Street Journal December 19, 2023 11:55 UTC